Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Alerts
  • Advertising/recruitment
  • Subscribe
  • Contact
  • Current Issue
  • Past Issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • 100th Anniversary of Insulin's Discovery (Jan 2021)
    • Hypoxia-inducible factors in disease pathophysiology and therapeutics (Oct 2020)
    • Latency in Infectious Disease (Jul 2020)
    • Immunotherapy in Hematological Cancers (Apr 2020)
    • Big Data's Future in Medicine (Feb 2020)
    • Mechanisms Underlying the Metabolic Syndrome (Oct 2019)
    • Reparative Immunology (Jul 2019)
    • View all review series ...
  • Viewpoint
  • Collections
    • Recently published
    • In-Press Preview
    • Commentaries
    • Concise Communication
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • Recently published
  • In-Press Preview
  • Commentaries
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Alerts
  • Advertising/recruitment
  • Subscribe
  • Contact
α–Intercalated cells defend the urinary system from bacterial infection
Neal Paragas, … , Adam J. Ratner, Jonathan Barasch
Neal Paragas, … , Adam J. Ratner, Jonathan Barasch
Published June 17, 2014
Citation Information: J Clin Invest. 2014;124(7):2963-2976. https://doi.org/10.1172/JCI71630.
View: Text | PDF | Erratum
Research Article

α–Intercalated cells defend the urinary system from bacterial infection

  • Text
  • PDF
Abstract

α–Intercalated cells (A-ICs) within the collecting duct of the kidney are critical for acid-base homeostasis. Here, we have shown that A-ICs also serve as both sentinels and effectors in the defense against urinary infections. In a murine urinary tract infection model, A-ICs bound uropathogenic E. coli and responded by acidifying the urine and secreting the bacteriostatic protein lipocalin 2 (LCN2; also known as NGAL). A-IC–dependent LCN2 secretion required TLR4, as mice expressing an LPS-insensitive form of TLR4 expressed reduced levels of LCN2. The presence of LCN2 in urine was both necessary and sufficient to control the urinary tract infection through iron sequestration, even in the harsh condition of urine acidification. In mice lacking A-ICs, both urinary LCN2 and urinary acidification were reduced, and consequently bacterial clearance was limited. Together these results indicate that A-ICs, which are known to regulate acid-base metabolism, are also critical for urinary defense against pathogenic bacteria. They respond to both cystitis and pyelonephritis by delivering bacteriostatic chemical agents to the lower urinary system.

Authors

Neal Paragas, Ritwij Kulkarni, Max Werth, Kai M. Schmidt-Ott, Catherine Forster, Rong Deng, Qingyin Zhang, Eugenia Singer, Alexander D. Klose, Tian Huai Shen, Kevin P. Francis, Sunetra Ray, Soundarapandian Vijayakumar, Samuel Seward, Mary E. Bovino, Katherine Xu, Yared Takabe, Fábio E. Amaral, Sumit Mohan, Rebecca Wax, Kaitlyn Corbin, Simone Sanna-Cherchi, Kiyoshi Mori, Lynne Johnson, Thomas Nickolas, Vivette D’Agati, Chyuan-Sheng Lin, Andong Qiu, Qais Al-Awqati, Adam J. Ratner, Jonathan Barasch

×

Figure 1

LCN2 is markedly upregulated in human and mouse UTI.

Options: View larger image (or click on image) Download as PowerPoint
LCN2 is markedly upregulated in human and mouse UTI.
(A) uLCN2 expressio...
(A) uLCN2 expression in LE+Cx+ (100 ng/ml; IQR 30–300 ng/ml; n = 43) versus LE–Cx– patients (14.2 ng/ml; IQR 7.4–35.3 ng/ml; n = 514) in an Emergency Department cohort lacking other forms of kidney disease. (B) Relationship between uLCN2 and uCFU in all LE+ Emergency Department patients (LE+ and <104 uCFU [limit of detection], 45 ng/ml uLCN2, IQR 20–150 ng/ml, n = 75; LE+ and 104–105 uCFU, 250 ng/ml, IQR 40–425 ng/ml, n = 21; LE+ and >105 uCFU, 520.2 ng/ml, IQR 236.7–1,126 ng/ml, n = 45). (C) Suppression of uLCN2 by antibiotics (Pre, 600 ng/ml, IQR 533–700 ng/ml; Post, 83.0 ng/ml, IQR 21–129 ng/ml) in patients presenting to clinic with dysuria, frequency, urgency and LE+ (>30 wbc per high-powered field), hematuria, and mucus threads (n = 4). Values represent median and IQR.
Follow JCI:
Copyright © 2021 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts